Famicord Ag · XETR:V3V
Famicord — Investor Presentation (November 2025)
24 slides from Famicord's investor presentation, Nov 25, 2025
Slide 1: Company Presentation
Company Presentation November 2025
Slide 2: Jakub Baran, CEO
Jakub Baran CEO Company Presentation - November 2025
Slide 3: FamiCord in Europe and beyond
FamiCord in Europe and beyond Broad geographical coverage • No. 1 in Europe • No. 3 in the world • ~55% of market share in Europe • > 1 million of samples stored • 13 processing labs • 2 storage labs • 2 CDMO centers • CAR-T dedicated R&D team Company Presentation - November 2025 3 Source: FamiCord
Slide 4: Value Chain of our Family Banking Service
Value Chain of our FAMILY BANKING SERVICE 1. 2. 3. 4. 5. 6. 7. Information Order via Collection Shipping to Processing Storage in Possible via doctors, Internet, in partner FamiCord in the controlled treatment midwives, contract, hospitals within max. laboratory, process based on health medical and
Slide 5: Family banking penetration
Family banking penetration Very diverse picture • European penetration is below 2%, with potential to grow at least to US levels (3-4%). • The highest penetration in Europe continues to be in Portugal, Hungary and Romania. • Spain should grow due to the ruling of the Highest Court enabling collectio
Slide 6: Industry hit by three black swans
Industry hit by three black swans Each of them separately could be considered as a black swan for the industry ↘ Live births EU-27 ↘ Ex-leader bankruptcy in 2019 COVID 2020 4.500.000 • Biggest impact: trust toward the industry was hit • Off-line channels were hit dramatically. The service of stem-ce
Slide 7: Subscription Revenues
Subscription Revenues Powerhorse of cash generation Invoiced net annual storage fee in the B2C segment in mEUR in k units Number of B2C clients in 25,0 21,0 19,7 annual subscription model Subscription / Prepayment 20,0 17,6 15,7 235,7 249,1 262,4 Client split in 2024 15,0 12,9 14,0 11,6 200,7 216,9
Slide 8: Cash revenues from clients' base
Cash revenues from clients’ base Gradual growth of revenue stream from already stored samples Expiring existing prepayment contracts 2023-2027 Annually paying Prolongations in Existing clients buying Expiring existing prepayment contracts clients prepayments extra services 18.000 15.845 16.000 Cash
Slide 9: Roll-out of placenta banking
ROLL - OUT of placenta BANKING Placenta is naturally considered as „source of life” LAUNCHED MARKET EXPERIENCE BUSINESS EFFECTS EXPECTED • We have an excellent experience from Switzerland as well as • We have an excellent experience from Switzerland as well as from from GCC in terms of service accep
Slide 10: Commercial Update and Outlook
Commercial Update and Outlook
Slide 11: Group financials – 9M 2025
Group financials – 9M 2025 IFRS, in EUR '000 FINANCIAL HIGHLIGHTS Q3 Q3 9M 9M 2025 2024 2025 2024 ∆ • Strong earnings conversion continues: Group revenue 22,789 22,232 66,365 60,261 10.1% disproportionally higher EBITDA and EBIT Gross profit 9,773 9,035 27,627 23,645 16.8% * • Net profit positive ag
Slide 12: Regional development
Regional development Markets remain challenging… …but we seem to have found a remedy! • Investments into Sales & Marketing continue to show effects • Eastern Europe: continued positive demand • Central Europe: mixed picture, but clearly stabilization continues, further deterioration stopped • Southe
Slide 13: Outlook 2025 confirmed
Outlook 2025 confirmed GROUP REVENUES GROUP EBITDA EUR 85 – 95 m EUR 8.7 – 10.3 m • We continue to improve our market share as well as market postion in selected countries • Overall optimistic about 2025 and beyond • Keeping firm grip on costs and realize potential savings • Growing demand for contr
Slide 14: Thank you for your attention
Thank you for your attention Contact • Jakub Baran (CEO) [email protected] Perlickstraße 5, 04103 Leipzig, Germany Tel. +49 341 48792 7574 • Thomas Pfaadt (CFO) [email protected] Fax +49 341 48792 39 • Ingo Middelmenne (IRO) [email protected] www.famicord.com
Slide 15: Back Up
$¢ FamiCord MORE THAN A STEM CELL BANK BACK UP
Slide 16: Market situation
Market situation Strong position indicates obvious growth directions Higer share caused by: Countries • FamiCord better market ~67% of operation share in smaller FamiCord holds ~67% market share (B2C and B2B), averaged countries across countries of presence based on the percentage of • Countries Fam
Slide 17: Empowered purpose, mission and vision
Empowered purpose, mission and vision Identity Purpose Mission Vision FamiCord, as the first and leading We preserve cells for Our mission is to empower We envision a future where European provider in stem cell personalized therapies families with personalized cell banking and advanced banking, has
Slide 18: Europe: On-going market consolidation
Europe: On-going market consolidation Stem cell banking industry becoming mature 15 YEARS AGO 5 YEARS AGO TODAY TOMORROW ~150 <100 ~60 40? PLAYERS PLAYERS PLAYERS PLAYERS • Some players have own lab while the others outsource the services. • Percentage of companies having own lab is going up, so mos
Slide 19: More stem cell therapies trigger more interest in cell banking
More stem cell therapies trigger more interest in cell banking Strenghts Oportunities • Stem cell therapies are overall considered very safe • Clinical trials advancing with good results • Close to 1000 clinical trials with stem cells going-on • Developments in science in China and US • Solution for
Slide 20: It works! Stem cells are key to development of new therapies
It works! Stem cells are key to development of new therapies Cord blood Number of active cell recommended in therapies in clinical trials treatment of cerebral 1600 palsy at children (first 1400 country approval in 1200 Australia in Q2 2025) 1000 800 1487 600 1178 400 910 200 0 Stem Cell Allogeneic
Slide 21: New medical data supporting banking are available
New medical data supporting banking are available AUG-2025 The European Commission has granted conditional authorization for Zemcelpro® (UM171 Cell Therapy) – the first therapy based on the expansion of umbilical cord blood stem cells. This innovation offers new hope for adult patients with blood ca
Slide 22: Countries of focus
Countries of focus Each country requires individual approach Germany Poland Spain • Leveraging from investment in sales • Further development of the stem cell • Opening CB collections in the new and marketing done in 2024 therapies with clinics regions and hospitals based on the • Building cooperati
Slide 23: Executive Summary
Executive Summary Growth building blocks Ambition – substantially increase value for FamiCord shareholders BECOME THE BANK OF THE OBVIOUS CHOICE OF THE FAMILIES Much broader B2B partnerships in therapies as Growing effect of Snowball effect of well as with HCP Sales & operational Increase of CLTV cu
Slide 24: Consolidated Financial Statements 2024
Consolidated Financial Statements 2024 Consolidated Income Statement (IFRS) TEUR 2023 2024 ∆ abs ∆ [%] 1. Sales revenue 77.062 82.184 5.122 6,6% 2. Cost of sales -48.818 -61.530 -12.712 26,0% 3. Gross result 28.244 20.654 -7.590 -26,9% Gross margin 36,7% 25,1% -11,6pp 4. Marketing and selling expens